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ANTIDEPRESSANT USE AND FDA WARNINGS
Authors’ reply to Olfson and Schoenbaum, Nardo,
Bartlett, Moore, Case, Gøtzsche, and Barber and
colleagues
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1Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA; 2Group Health Research
Institute, Seattle, WA, USA
We agree with Olfson and Schoenbaum about the need for more
systematic use of cause of injury codes.1 2 Public health efforts
to understand and reduce suicide risk depend on accurate data.
Indeed, this problem (varying use of these codes across and
within health systems over time) motivated us to use a proxy
measure for suicide attempts.
Several comments question the sensitivity of this proxymeasure
(the proportion of suicide attempts by psychotropic drug
poisoning).3-5
Olfson and Schoenbaum cite US national data that sensitivity
is likely to be no more than 50%. The use of these data is,
however, problematic given the inconsistent use of cause of
injury codes.We examined this question in three of our research
network health systems where these codes are used regularly.
We found that the proportion of suicide attempts (by cause of
injury code) across age groups and health systems ranged from
roughly 30% to 60%. A sensitivity of 30% to 60% means that
this proxy measure would not be appropriate for estimating
prevalence, and reduced sensitivity would reduce statistical
power for detecting changes over time, although it would not
bias our interrupted time series analysis.
Olfson and Schoenbaum also say that only a small proportion
of emergency department visits for poisoning entail psychotropic
drugs. Their data, however, concern intentional poisoning
(poisoning by someone else) rather than self inflicted poisoning
(intentional overdose).
More important for our study is the question of positive
predictive value—the proportion of psychotropic poisonings
that are intentional overdoses according to cause of injury code.
We also examined this question in three of our member health
systemswhere these codes are used regularly. Positive predictive
values ranged from 35% to 80% across health systems and age
groups, and from 62% to 80% in adolescents, the group of
greatest interest.
Nevertheless, we acknowledge that psychotropic poisoning is
an imperfect proxy for suicide attempts and that its use might
reduce the sensitivity of our methods. But this proxy measure
is preferable to cause of injury codes in settings where code
usage varies over time (thereby precluding valid time series
analysis).
In the evaluation of policies or regulatory changes (such as the
antidepressant safety warnings), true experiments or randomised
trials are usually not possible. We agree with Olfson and
Schoenbaum that quasi-experimental or observational studies
are open to varying interpretation. In support of our
interpretation, we emphasise two points.
Firstly, our study question and methods were specified in
advance.
Secondly, our results do not indicate a gradual trend in rates of
antidepressant use or psychotropic drug poisonings but a
discontinuity or change in slope at a time (specified a priori)
corresponding to the Food and Drug Administration (FDA)
warnings and related publicity. We stand by our conclusion that
these warnings, however well intentioned, seem to have had
unintended effects.
We considered the stratified analysis proposed by Case6 but
decided it would not be valid. Rates of antidepressant use
decreased considerably after the warnings, and it is reasonable
to presume that this reduction was not random. If, for example,
decreased antidepressant use was concentrated among those
with less severe depression, this would bias any comparison
that was limited to either antidepressant users or non-users.
Gøtzsche’s comments focus on our inability to directly address
clinical questions about the efficacy and safety of antidepressants
in young people.7 We agree. A policy evaluation study cannot
directly answer efficacy and safety questions that should be
investigated by randomised trials. But the opposite also holds.
Randomised trials to evaluate efficacy and safety cannot
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accurately predict the consequences of policy or regulatory
decisions. Of note, meta-analyses of randomised trials of
antidepressants did not examine effects on suicide attempts,
only on a broad category of “suicidal ideation or behaviours.”
But even if trials showed that antidepressants increased the risk
of suicide attempts in young people, it does not necessarily
imply that a warning from the FDA would reduce this risk. Our
data do not indicate that the warning reduced the risk of suicide
attempts in adolescents and young adults.
Discontinuities or abrupt reductions in antidepressant
prescriptions, which were consistent with previously published
articles, suggest changes in patient care after the FDAwarnings.
Importantly, these studies found substantial reductions in
antidepressant use and no compensating increases in the use of
treatment alternatives among young people after the warnings.
Our interpretation that the warnings may be associated with
undertreatment of mood disorders among young people is based
on all of these data, not reduced antidepressant use alone. In
addition, sudden changes in patient care may have negative
effects. Our data certainly do not indicate that the FDAwarnings
reduced suicidal behaviour in adolescents and young adults.
Adults who were not targeted by the warnings (“comparison”
group) had smaller reductions in antidepressant use, and other
studies found compensating increases in use of treatment
alternatives. There was no change in suicidal behaviour among
adults. Given limited research funding, we focused on three
outcomemeasures and did not measure reductions in depression
diagnoses over time, which have already been shown in other
studies of our network of US health plans.
We considered the additional national data provided by Barber
and colleagues.8 However, data on self harm from
WISQUARS-non-fatal emergency department visits (ages
10-17) seem to show spikes in years 2004 and 2005, which
coincided with the timing of the FDA warnings, but without
longer baseline data and appropriate statistical analysis we could
not draw definitive conclusions. Our figure on completed
suicides in adolescents shows a similar pattern to that of Barber
and colleagues, which is based on the CDC WISQARS-fatal
website. We are not aware that measures from the youth risk
behaviour survey have been validated.
Finally, the most important implication of our study is the need
for better risk communication of serious drug warnings through
improved coordination between the lay press and the FDA. This
should include more holistic consideration of both non-drug
and drug treatments and their benefits and risks for evidence
based patient care.
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